Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.

Trial Profile

Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 May 2016

At a glance

  • Drugs Squalamine (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms IMPACT
  • Sponsors Ohr Pharmaceutical
  • Most Recent Events

    • 10 May 2016 Results of analysis of lesion characteristics as predictors of visual outcome were presented at the Association for Research in Vision and Ophthalmology (ARVO) Conference 2016, according to an Ohr Pharmaceutical media release.
    • 16 Nov 2015 According to an Ohr Pharmaceuticals media release, additional data from this trial has been presented at the annual meeting of the American Academy of Ophthalmology (AAO).
    • 16 Nov 2015 Results published in the Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top